[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-563872-105":59,"doc-detail-563872-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","efficacy-and-safety-of-transarterial-chemoembolization-combined-with-lenvatinib-and-pd-1-inhibitor-in-advanced-hepatocellular-carcinoma-a-meta-analysis","Efﬁcacy and safety of transarterial chemoembolization combined with lenvatinib and PD-1 inhibitor in the treatment of advanced hepatocellular carcinoma - A meta-analysis","","The study evaluates benefits and potential adverse effects of transarterial chemoembolization (TACE) combined with lenvatinib and PD-1 protein inhibitors for advanced hepatocellular carcinoma (HCC). A systematic search of multiple databases collected studies published from inception to May 2023. Included clinical trials examined TACE plus lenvatinib and PD-1 inhibitors versus other regimens, and outcomes were pooled using fixed- or random-effects models as hazard ratios or risk ratios with 95% confidence intervals. Thirteen cohort studies (1279 patients) showed improved overall survival, progression-free survival, objective response rate, and disease control rate without significant differences in all-grade or grade ≥3 adverse events. Prognostic analyses identified several independent factors for survival endpoints, and trial sequential analysis supported adequacy for ORR and DCR conclusions.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/efficacy-and-safety-of-transarterial-chemoembolization-combined-with-lenvatinib-and-pd-1-inhibitor-in-advanced-hepatocellular-carcinoma-a-meta-analysis/563872/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/efficacy-and-safety-of-transarterial-chemoembolization-combined-with-lenvatinib-and-pd-1-inhibitor-in-advanced-hepatocellular-carcinoma-a-meta-analysis/563872.png","ImageObject",300,407,{"name":92,"@type":93},"Lucas Martin","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-16","2026-10-12",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What treatment combination does the meta-analysis assess for advanced hepatocellular carcinoma?","Question",{"text":112,"@type":113},"It assesses transarterial chemoembolization (TACE) combined with lenvatinib and PD-1 protein inhibitors as a therapeutic approach for advanced hepatocellular carcinoma.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the studies and outcomes synthesized in the analysis?",{"text":117,"@type":113},"Relevant studies were identified through a systematic search up to May 2023 and pooled using fixed- or random-effects models, reporting hazard ratios or risk ratios with 95% confidence intervals.",{"name":119,"@type":110,"acceptedAnswer":120},"What main efficacy and safety findings were reported?",{"text":121,"@type":113},"The combined approach significantly improved overall survival, progression-free survival, objective response rate, and disease control rate versus other regimens, while all-grade and grade ≥3 adverse event incidences were comparable without significant differences.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},563872,1792231370,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Pharmacology & Therapeutics 257 (2024) 108634  \nContents lists available at ScienceDirect  \nPharmacology & Therapeutics  \njournal [homepage:](homepage: www. elsevier. com/locate/pharmthera)[ www. elsevier. com/locate/pharmthera](homepage: www. elsevier. com/locate/pharmthera)  \nEfﬁcacy and safety of transarterial chemoembolization combined with lenvatinib and PD-1 inhibitor in the treatment of advanced hepatocellular carcinoma: A meta-analysis  \nLei Wang a, Li Linb, Wei Zhou c,⁎  \na Department of Vascular and Thyroid Surgery, The First Afﬁliated Hospital of China Medical University, Shenyang, China  \nb Department of Pulmonary and Critical Care Medicine, The First Afﬁliated Hospital of China Medical University, Shenyang, China c Department of Organ Transplantation and Hepatobiliary Surgery, The First Afﬁliated Hospital of China Medical University, Shenyang, China  \n\n| a r t i c l e i n f o |  | a b s t r a c t |\n| --- | --- | --- |\n| Available online 16 March 2024 |  | The study aims to evaluate the beneﬁts and potential adverse effects of transarterial chemoembolization (TACE) combined with lenvatinib and programmed cell death 1 (PD-1) protein inhibitors in the treatment of advanced hepatocellular carcinoma (HCC). A systematic literature search of several databases for relevant studies, published from inception up to May 2023, was performed. Clinical trials investigating TACE combined with lenvatiniband PD-1 inhibitors compared with other treatment regimens for advanced HCC were included. Data were pooled using ﬁxed-or random-effects models and expressed as hazard ratios (HRs) or risk ratios (RRs) with corresponding 95% conﬁdence interval (CI). Trial sequential analysis was used to determine whether the study results were sufﬁciently conclusive. Totally thirteen cohort studies comprising 1279 patients were included. The combined use of TACE, lenvatinib, and PD-1 inhibitors signiﬁcantly improved overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR) compared with other treatment regimens. The incidences of all-grade or grade ≥ 3 adverse events were comparable and did not differ signiﬁcantly between the two groups. Prognostic factor analysis identiﬁed treatment options, portal vein tumor thrombus, extrahepatic metastasis, and Barcelona Clinic Liver Cancer (BCLC) stage as independent prognostic factors for OS. Extrahepatic metastasis, Child–Pugh score, and hepatic vein invasion emerged as independent prognostic factors for PFS. TSA suggested that the available data were adequate for drawing numerical conclusions regarding ORR and DCR. An approach combining TACE, lenvatinib, and PD-1 inhibitors appeared to offer signiﬁcant improvements in OS, PFS, ORR, and DCR in patients with advanced HCC without signiﬁcantly increasing the risk for all-grade adverse events.\u003Cbr>© 2024 Elsevier Inc. All rights reserved. |\n| Associate Editor: Dr. Beverly Teicher\u003Cbr>Keywords: TACELenvatinib PD-1 inhibitors\u003Cbr>Hepatocellular carcinoma meta-analysis |  |  |\n\nContents  \n1. Introduction ............................................... 2  \n2. Study design ............................................... 2  \n3. Findings ................................................. 3  \n4. Discussion ................................................ 9  \nFunding .................................................... 10  \nAuthor's contributions ............................................. 10  \nCRediT authorship contribution statement .................................... 10  \nAbbreviations: AEs, adverse events; BCLC, Barcelona Clinic Liver Cancer; CI, conﬁdence interval; DCR, disease control rate; HCC, hepatocellular carcinoma; uHCC, unresectable HCC; HR, hazard ratio; ICIs, immune checkpoint inhibitors; ORR, objective response rate; OS, overall survival; PD-1, programmed death-1; PD-L1, programmed death ligand-1; PFS, progression-free survival; RCT, randomized controlled trial; RR, risk ratio; TACE, transarterial","cbCairSure3WstyK","https://ap.wps.com/l/cbCairSure3WstyK","pdf",2069269,11,"English","# Introduction\n# Study design\n# Findings\n# Discussion\n## Funding\n## Author's contributions\n## CRediT authorship contribution statement\n## Abbreviations\n## Declaration of competing interest\n## Acknowledgment\n## References","[{\"question\":\"What treatment combination does the meta-analysis assess for advanced hepatocellular carcinoma?\",\"answer\":\"It assesses transarterial chemoembolization (TACE) combined with lenvatinib and PD-1 protein inhibitors as a therapeutic approach for advanced hepatocellular carcinoma.\"},{\"question\":\"How were the studies and outcomes synthesized in the analysis?\",\"answer\":\"Relevant studies were identified through a systematic search up to May 2023 and pooled using fixed- or random-effects models, reporting hazard ratios or risk ratios with 95% confidence intervals.\"},{\"question\":\"What main efficacy and safety findings were reported?\",\"answer\":\"The combined approach significantly improved overall survival, progression-free survival, objective response rate, and disease control rate versus other regimens, while all-grade and grade ≥3 adverse event incidences were comparable without significant differences.\"}]","Efﬁcacy and safety of transarterial chemoembolization combined with lenvatinib and PD-1 inhibitor in the treatment of advanced hepatocellular carcinoma - A meta-analysis | PDF",1791839081,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/4d09082eea73d85bdf91cfd19f4aae22.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/95efe37e9f7112c688c7a6ba09e24fcc.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/7cb87ce07770a1dc095c3bac49df899e.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/83af53f4d531b1197ae35a406d56fa5e.webp",980,1306]